Pain-Free, Non-Narcotic Plastic Surgery Recovery: The Role of Suzetrigine — JOURNAVX®
Learn how JOURNAVX® (suzetrigine), a first-in-class non-opioid pain medication, may support opioid-sparing plastic surgery recovery after procedures such as tummy tuck, breast augmentation, liposuction, and mommy makeover.
Schedule a ConsultationPOST-OPERATIVE PAIN MANAGEMENT
Pain-Free, Non-Narcotic Plastic Surgery Recovery: The Role of Suzetrigine — JOURNAVX®
One of the most important developments in modern plastic surgery recovery is the movement toward multimodal, opioid-sparing pain management.
The recovery goal
Control pain while keeping the patient comfortable, clear-headed, mobile, hydrated, and able to return to normal function as safely as possible.
- Comfortable
- Clear-headed
- Mobile
- Hydrated
- Returning to normal function safely
JOURNAVX®
FDA approved in 2025
For moderate to severe acute pain in adults.
FDA approved: 2025
Non-opioid oral medication
Indicated for moderate to severe acute pain in adults
The traditional approach: opioids
Hydrocodone and oxycodone have commonly been used for postoperative pain and can provide effective pain relief.
For many patients, however, these medications come with side effects they may wish to avoid:
- Nausea
- Constipation
- Sedation
- Dizziness
- Mental fog
A different approach
JOURNAVX is a first-in-class non-opioid oral medication indicated for moderate to severe acute pain in adults, approved by the FDA in 2025.
Rather than acting on opioid receptors, JOURNAVX targets a peripheral pain-signaling pathway.
For appropriate plastic-surgery patients, JOURNAVX may be incorporated into a broader multimodal recovery protocol designed to reduce reliance on narcotic medication.
At his Dallas plastic surgery practice, Dr. John L. Burns Jr. believes pain management should support recovery - not become another obstacle to it.
JOURNAVX® is a prescription medication. Suitability, contraindications, and recovery use should be determined by a qualified medical professional. This content is for educational purposes and is not medical advice.
PATIENT EDUCATION
What Is JOURNAVX®?
JOURNAVX® is the brand name for suzetrigine, a new non-opioid oral pain medication designed to relieve acute pain without acting on opioid receptors.
Non-opioid
Same goal — pain relief. Different biological pathway.
PAIN PATHWAY
How Does Suzetrigine Work?
Pain begins with signaling. An injury activates peripheral nerves that transmit electrical signals to the spinal cord and brain, and NaV1.8 sodium channels are part of that pathway.
Non-opioid · Non-controlled
- Surgery creates tissue injury and inflammation.
- Peripheral pain-sensing nerves become activated.
- Electrical pain signals travel through these nerves.
- NaV1.8 channels participate in that signaling.
- Suzetrigine inhibits NaV1.8.
- Pain signaling is reduced through a non-opioid mechanism.
JOURNAVX provides a fundamentally different approach to acute pain management.
It is not an opioid and is not a controlled substance.
RECOVERY
Why Non-Opioid Pain Management Matters in Plastic Surgery
Plastic surgery patients need more than pain relief.
My pain is manageable, and I still feel like myself.
Patients also need to:
- Walk
- Hydrate
- Eat appropriately
- Sleep
- Follow postoperative instructions
- Manage compression garments or drains when applicable
- Communicate with their surgical team
- Gradually resume normal activity
Common opioid-associated problems:
- Nausea
- Vomiting
- Constipation
- Sedation
- Dizziness
- Mental fog
- Itching
- Poor appetite
- Urinary retention
- Impaired balance
- Reduced mobility
- Risk of misuse or dependence
The goal of opioid-sparing recovery is not simply to eliminate a category of medication — it is to create a more functional recovery experience.
MULTIMODAL RECOVERY
JOURNAVX and Multimodal Plastic Surgery Recovery
JOURNAVX is not the entire recovery protocol. Modern postoperative care often uses a multimodal strategy that combines several methods to address pain through different mechanisms.
Non-opioid · Adjunct
A recovery plan may incorporate:
The exact protocol should always be individualized. A breast augmentation patient does not necessarily need the same recovery plan as someone undergoing a tummy tuck with muscle repair.
CANDIDATE PROCEDURES
Procedures That May Benefit From an Opioid-Sparing Approach
Non-opioid and opioid-sparing recovery strategies may be considered across many aesthetic procedures. The type and intensity of discomfort varies considerably between them.
Breast
Breast augmentation
Breast lift
Breast reduction
Breast revision
Body
Tummy tuck
Mommy makeover
VASER liposuction
Lipo 360
Body contouring
Fat transfer
Face
Facelift
Neck lift
Eyelid surgery
Breast augmentation may produce tightness and pressure, while tummy tuck patients can experience discomfort associated with abdominal-wall repair. Facelift patients often have a different pain profile, but avoiding nausea, excessive sedation, and blood-pressure fluctuations can still matter during recovery.
The recovery plan should fit the operation and the patient.
CLINICAL EVIDENCE
JOURNAVX After Tummy Tuck Surgery
Tummy tuck surgery is particularly relevant to the discussion surrounding suzetrigine, and one of the pivotal Phase 3 trials supporting FDA approval studied patients with moderate to severe acute pain following full abdominoplasty.
Phase 3 · Abdominoplasty
Trial at a glance
Population
Adults with moderate to severe acute pain after full abdominoplasty
Comparators
Placebo and an active hydrocodone/acetaminophen arm
Primary endpoint
Pain relief — suzetrigine showed statistically significant improvement vs placebo
Secondary endpoint
Did not demonstrate superiority to hydrocodone/acetaminophen on the first key secondary efficacy endpoint
What the evidence supports
The trial results draw a careful line between what suzetrigine clearly achieved and where it did not separate from an opioid comparator.
Suzetrigine vs Placebo
Statistically significant improvement on the primary pain-relief endpoint.
Suzetrigine vs Hydrocodone/Acetaminophen
Did not demonstrate superiority on the first key secondary efficacy endpoint.
JOURNAVX should not be presented as universally providing stronger analgesia than opioid medication.
Its potential value is the ability to manage acute pain through a non-opioid mechanism.
PRESCRIBING REFERENCE
JOURNAVX® Dosing
For adults with normal hepatic function who are not taking medications requiring dose modification, the FDA-approved regimen begins with a 100 mg starting dose followed by 50 mg every 12 hours.
FDA-approved · Adults
Starting dose
100 mg orally once
Take on an empty stomach, at least 1 hour before or 2 hours after food. Clear liquids are permitted.
Then, beginning 12 hours later
50 mg orally every 12 hours
Subsequent doses may be taken with or without food.
Routine
Swallow whole · Avoid grapefruit
Do not crush or chew. Avoid food and drinks containing grapefruit during treatment.
Key administration considerations
The following points support safe, consistent use of JOURNAVX throughout treatment.
This information is educational and is not a substitute for individualized prescribing instructions. Patients should take JOURNAVX only as prescribed by their treating healthcare professional.
CANDIDATE PROFILE
Who May Be a Candidate for JOURNAVX?
JOURNAVX may be considered as part of a postoperative pain-management plan for appropriate adults who meet specific criteria, listed below
Are expected to experience moderate to severe acute postoperative pain
Want to reduce exposure to opioid medications
Have previously experienced undesirable opioid effects
Prefer a clearer, more functional recovery when medically appropriate
Can follow the prescribed dosing schedule
Do not have contraindicated drug interactions
Are appropriate candidates after medical and medication review
Not for everyone
No pain medication is appropriate for everyone. JOURNAVX requires a medical and medication review before use.
General principle
Patient selection remains essential. Suitability depends on the procedure, the patient's history, and the prescribing clinician's judgement.
The goal is to match the medication to the patient — and the operation.
SAFETY REFERENCE
Important Drug Interactions and Precautions
Before prescribing JOURNAVX, the surgical team should review the patient's medications, supplements, medical history, and liver function when relevant.
Safety reference
Strong CYP3A inhibitors
Contraindicated with JOURNAVX.
Strong or moderate CYP3A inducers
Use should be avoided.
Certain moderate CYP3A inhibitors
Dose modification is required.
Grapefruit
Avoid grapefruit-containing food or beverages while taking the medication.
Medication review
A complete review of medications and supplements is an important part of surgical planning.
Hepatic and hormonal considerations
These two areas require particular attention when planning treatment with JOURNAVX.
These considerations are why a complete medication review is an important part of surgical planning.
SAFETY PROFILE
Does JOURNAVX Have Side Effects?
JOURNAVX is non-opioid, but non-opioid does not mean side-effect-free — the adverse reactions seen more often with JOURNAVX than placebo in the controlled clinical trials supporting approval are listed below.
Pruritus (itching)
Reported more often than with placebo in the approval trials.
Muscle spasms
Reported more often than with placebo in the approval trials.
Increased blood creatine phosphokinase
Lab marker elevation reported more often than with placebo in the approval trials.
Rash
Reported more often than with placebo in the approval trials.
Patients should discuss potential risks, interactions, and benefits with their prescribing physician.
EVIDENCE-BASED ANSWER
Is JOURNAVX Better Than Opioid Pain Medication?
This question requires an evidence-based answer; the trials showed clear benefit versus placebo but did not establish superiority over hydrocodone/acetaminophen.
Evidence-based answer
What the trials showed
Statistically significant pain reduction compared with placebo following abdominoplasty and bunionectomy.
What the trials did not show
Superiority over hydrocodone/acetaminophen on the first key secondary efficacy endpoint.
Its importance is different
The value of JOURNAVX is not framed as being universally stronger than opioids.
JOURNAVX should not be described as universally stronger or more effective than opioid pain medication.
Its importance is different. It provides an effective, FDA-approved non-opioid option for moderate to severe acute pain.
For appropriate patients, that creates an opportunity to control postoperative pain while potentially reducing reliance on opioids and avoiding some of the disadvantages associated with opioid exposure.
EXPECTATIONS
Non-Narcotic Does Not Mean 'No Pain'
Expectations matter; no responsible recovery protocol should promise a completely pain-free surgical experience, and the sensations listed below are normal parts of healing.
Soreness
Tightness
Pressure
Swelling
Tenderness
Muscle discomfort
Temporary changes in sensation
These are normal components of healing after many procedures.
The objective is to keep discomfort manageable and compatible with healthy recovery.
A successful rapid-recovery protocol helps the patient move, eat, hydrate, rest, and gradually resume normal activities without unnecessary medication-related impairment.
PRACTICE PHILOSOPHY
Why Dr. Burns Emphasizes Rapid Recovery
Dr. Burns' philosophy is that surgical technique and postoperative recovery should work together; the operation should be performed precisely and efficiently, while the recovery protocol should help patients regain normal function as safely as possible.
Practice philosophy
An ideal recovery plan should seek to:
Where JOURNAVX fits
Thinking beyond pain scores alone is what makes the philosophy actionable.
JOURNAVX gives surgeons another tool that may help accomplish these goals in appropriately selected adults.
The operation should be performed precisely and efficiently — and the recovery protocol should help patients get back to themselves.
LOOKING AHEAD
The Future of Plastic Surgery Recovery
Plastic surgery has become increasingly sophisticated, and pain management should evolve alongside it. The FDA approval of suzetrigine introduced the first medication in a new class of non-opioid analgesics for moderate to severe acute pain.
Looking ahead
Plastic surgery has become increasingly sophisticated
- Incisions are more precise
- Surgical planning has improved
- Anesthesia techniques have advanced
- Breast augmentation can incorporate rapid-recovery principles
- Tummy tuck and body-contouring techniques continue to evolve
Where JOURNAVX fits in the bigger picture
JOURNAVX does not eliminate the need for careful surgical technique, local anesthesia, multimodal pain management, patient education, or individualized postoperative care.
And it does not mean every patient can — or should — avoid opioids entirely.
Instead, it expands the options available to surgeons and patients.
The future of plastic surgery recovery is not simply about having less pain. It is about recovering comfortably while remaining clear, mobile, functional, and engaged in the healing process.
For plastic surgery, this is particularly notable because one of its pivotal efficacy trials involved patients following abdominoplasty.
FREQUENTLY ASKED QUESTIONS
Frequently Asked Questions
Short patient-facing answers to the most common questions about JOURNAVX, based on current prescribing information and the pivotal trials discussed earlier in this post.
9 common questions
DALLAS · PLASTIC SURGERY
Schedule a Rapid Recovery Plastic Surgery Consultation in Dallas
Dr. John L. Burns Jr. is a board-certified plastic surgeon in Dallas, Texas with more than 25 years of experience in aesthetic surgery of the face, breast, and body, and his practice emphasizes advanced surgical technique, individualized treatment planning, and modern recovery protocols.
John L. Burns Jr., MD, FACS
Board-Certified Plastic Surgeon
Dallas, Texas | 25+ Years of Experience
Phone: 214-515-0002
Website: DrJohnBurns.com
Depending on the patient and procedure, a postoperative plan may incorporate multiple opioid-sparing strategies, including local anesthesia, appropriate non-opioid medications, early mobility, careful postoperative monitoring, and JOURNAVX when clinically appropriate.
During consultation, Dr. Burns can discuss the entire surgical experience — not only what happens in the operating room, but also anesthesia, postoperative pain management, activity, recovery expectations, and the safest path back to normal life.
Medical Disclaimer
This article is for general educational purposes and does not constitute medical advice or prescribing guidance. JOURNAVX is a prescription medication. Medication selection, dosing, contraindications, interactions, and postoperative pain management should be determined by a qualified healthcare professional based on the individual patient.